 Specifically, GLP-1 has gotten a lot of attention lately because it's the target for the diabetes drug Ozempic and the weight loss injection Wegovi. The study showed that mice with diabetes and obesity responded well to oral doses of l-enolic acid. After a month, they had lost about 10% of their body weight and achieved insulin sensitivity comparable to normal mice.